doi: 10.5489/cuaj.10124.
2010 Update: Guidelines for the management of benign prostatic hyperplasia
Affiliations
- PMID: 20944799
- PMCID: PMC2950766
- DOI: 10.5489/cuaj.10124
Item in Clipboard
2010 Update: Guidelines for the management of benign prostatic hyperplasia
Can Urol Assoc J.
2010 Oct.
No abstract available
Figures
Diagnostic algorithm. LUTS = lower urinary tract symptoms; PE = physical examination; U/A = urinalysis; PSA = prostate-specific antigen; PVR = post-void residual.
Therapeutic algorithm. LUTS = lower urinary tract symptoms.
Similar articles
-
Translation of benign prostatic hyperplasia guidelines into clinical practice.Curr Opin Urol. 2008 Jan;18(1):56-60. doi: 10.1097/MOU.0b013e3282f13bbf. Curr Opin Urol. 2008. PMID: 18090491 Review.
-
[Evaluation of the impact of CTMH guidelines on the management of benign prostatic hyperplasia].Prog Urol. 2015 Jan;25(1):47-53. doi: 10.1016/j.purol.2014.09.049. Prog Urol. 2015. PMID: 25453357 French.
-
Investigation of benign prostatic hyperplasia.Curr Opin Urol. 2003 Jan;13(1):17-22. doi: 10.1097/00042307-200301000-00004. Curr Opin Urol. 2003. PMID: 12490811 Review.
-
[Surgical and interventional management of benign prostatic obstruction: Guidelines from the Committee for Male Voiding Disorders of the French Urology Association].Prog Urol. 2021 Apr;31(5):249-265. doi: 10.1016/j.purol.2020.12.006. Epub 2021 Jan 18. Prog Urol. 2021. PMID: 33478868 French.
-
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.J Urol. 2011 Sep;186(3):971-6. doi: 10.1016/j.juro.2011.04.081. Epub 2011 Jul 24. J Urol. 2011. PMID: 21791352
Cited by
-
Five-alpha reductase inhibitors and risk of prostate cancer among men with benign prostatic hyperplasia: A historical cohort study using primary care data.Wellcome Open Res. 2023 Jul 11;8:295. doi: 10.12688/wellcomeopenres.19566.1. eCollection 2023. Wellcome Open Res. 2023. PMID: 38774490 Free PMC article.
-
Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis.Sci Rep. 2024 May 15;14(1):11116. doi: 10.1038/s41598-024-61977-5. Sci Rep. 2024. PMID: 38750153 Free PMC article.
-
Safety of transurethral resection of large prostate.Urol Ann. 2023 Apr-Jun;15(2):162-165. doi: 10.4103/ua.ua_192_21. Epub 2023 Jan 16. Urol Ann. 2023. PMID: 37304516 Free PMC article.
-
Panax ginseng C.A. meyer alleviates benign prostatic hyperplasia while preventing finasteride-induced side effects.Front Pharmacol. 2023 Jan 12;14:1039622. doi: 10.3389/fphar.2023.1039622. eCollection 2023. Front Pharmacol. 2023. PMID: 36713838 Free PMC article.
-
Risk of prostate cancer and death after benign transurethral resection of the prostate-A 20-year population-based analysis.Cancer. 2022 Oct;128(20):3674-3680. doi: 10.1002/cncr.34407. Epub 2022 Aug 17. Cancer. 2022. PMID: 35975979 Free PMC article.
References
-
- Emberton M, Andriole GL, de la Rosette J, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology. 2003;61:267–73. - PubMed
-
- McConnell JD, Barry MJ, Bruskewitz RC, et al. Clinical practice guideline for benign prostatic hyperplasia: diagnosis and treatment. Rockville, Maryland: Agency for Health Care Policy and Research, Public Health Service; 1994. No. 94-0582, - PubMed
-
- AUA Guidelines on management of benign prostatic hyperplasia (2003) Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530–47. - PubMed
-
- de la Rosette J, Alivizatos G, Madersbacher S, et al. EUA Guidelines on benign prostatic hyperplasia (BPH) Eur Urol. 2001;40:256–63. - PubMed
-
- Madersbacher S, Alivizatos G, Nordling J, et al. EUA 2004 guidelines on assessment, therapy and follow up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH Guidelines) Eur Urol. 2004;46:547–54. - PubMed
LinkOut - more resources
Full Text Sources